Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-06-13
1994-07-26
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514281, 5142278, A61K 3144
Patent
active
053327470
ABSTRACT:
The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, representing various parasitic diseases, apparently by reversing the glycoprotein "pumps" associated with such cells.
REFERENCES:
Gralla et al. "Toxicology Studies With d-Tetrandrine (NSC-77037), a Plant Alkaloid With Vascular and Lymphotoxic Effects in Dogs and Monkeys." Cancer Chemotherapy Reports Part 3, vol. 5, No. 1, Sep. 1974, pp. 79-85.
Department of Pharmacology et al. "A Clinical Study of the Antihypertensive Effect of Tetrandrine." Chinese Medical Journal, 92(3): 193-198, 1979.
DeConti, Dr. Ronald C. "Phase I Initial Clinical Studies with d-Tetrandrine." Procter & Gamble Assoc. Cancer Res., 16, 96 (1975).
Molecular and Biochemical Parasitology, vol. 38 (1990), pp. 281-290 entitled "Emetine-resistant mutants of Entamoeba histolytica overexpress mRNAs for multidrug resistance".
"Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil" appearing in the Transactions of the Royal Society of Tropical Medicine and Hygiene, (1989), vol. 83, pp. 197-198.
Antimicrobial Agents and Chemotherapy, Jan. 1988, pp. 96-103 entitled "Inhibitors of Folic Acid Synthesis in the Treatment of Experimental Pneumocystis carinii Pneumonia".
"Effect of Bisbenzylisoquinoline (Biscoclaurine) Alkaloids on Multidrug Resistance in KB Human Cancer Cells," by Shiraishi et al. Cancer Research, vol. 47, pp. 2413-2416, May 1. 1987.
"Reversal of Chloroquine Resistance in Plasmodium falciparum by Verapamil," Martin, Oduola and Milhous, Science, Feb. 20, 1987, pp. 899-901.
"Biochemical Effects of d-Tetrandrine and Thalicarpine," William A. Creasey, Biochemical Pharmacology, vol. 25, pp. 1887-1892, Pergamon Press, 1976.
"Phosphorylation of the M.sub.R 170,000 to 180,000 Glycoproteins Specific to Multidrug-Resistant Tumor Cells: Effects of Verapamil, Trifluoperazine, and Phorbol Esters," by Hamada et al., Cancer Research, vol. 47, pp. 2860-2865, Jun. 1, 1987.
"Reversal of Chloroquine Resistance in Falciparum Malaria Independent of Calcium Channels," by Ye and Van Dyke, Biochemical and Biophysical Research Communications, vol. 155, No. 1, Aug. 30, 1988.
"Potentiation of Antitumor Activity of Vincristine by the Biscoclaurine Alkaloid Cepharanthine," by Kato and Suzumura, Journal of the National Cancer Institute, vol. 79, No. 3, Sep. 1987.
"Multidrug Resistance: Molecular Biology and Clinical Relevance," by Rothenberg and Ling, Journal of the National Cancer Institute, vol. 81, No. 12, Jun. 21, 1989.
"Multidrug Resistance in Cancer," Kartner and Ling, Scientific American, Mar. 1989.
Merck Index 10th Ed. 9056.
Chem Abstracts #75:59822w Mitscher et al.
Chem Abstracts #108:87627e Dreyfus et al. 1988.
Chem Abstracts #110:132058z Fournet et al. 1988.
Cancer Biologics of America, Inc.
Travers Russell
Waddell Frederick E.
LandOfFree
Method for potentiating primary drugs in treating multidrug resi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for potentiating primary drugs in treating multidrug resi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for potentiating primary drugs in treating multidrug resi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1053452